Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 9071 results

  1. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development Reference number: GID-TA10967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    Awaiting development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids

    In development Reference number: GID-HTG10470 Expected publication date: TBC

    HealthTech guidance
    In development

  6. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]

    Awaiting development Reference number: GID-TA11962 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  10. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]

    Awaiting development Reference number: GID-TA11551 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Delgocitinib for Chronic Hand Eczema [ID6688]

    Awaiting development Reference number: GID-TA11777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis

    Awaiting development Reference number: GID-HTG10536 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  15. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

    Quality standard
    Awaiting development